loading
전일 마감가:
$1.87
열려 있는:
$1.91
하루 거래량:
4.64M
Relative Volume:
4.03
시가총액:
$91.40M
수익:
-
순이익/손실:
$-67.68M
주가수익비율:
-1.0809
EPS:
-1.73
순현금흐름:
$-54.24M
1주 성능:
-38.28%
1개월 성능:
-56.41%
6개월 성능:
-84.17%
1년 성능:
-89.86%
1일 변동 폭
Value
$1.81
$2.01
1주일 범위
Value
$1.76
$3.0954
52주 변동 폭
Value
$1.76
$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
명칭
Cabaletta Bio Inc
Name
전화
(267) 759-3100
Name
주소
2929 ARCH STREET, PHILADELPHIA, PA
Name
직원
154
Name
트위터
@CabalettaBio
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
CABA's Discussions on Twitter

CABA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
CABA 1.87 91.40M 0 -67.68M -54.24M -1.73
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-09-05 개시 Citigroup Buy
2023-07-18 개시 Guggenheim Buy
2023-01-27 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-08-30 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-12-08 개시 Wells Fargo Overweight
2021-10-19 재개 Morgan Stanley Overweight
2021-06-30 개시 Mizuho Buy
2021-01-08 개시 Chardan Capital Markets Buy
2020-10-13 개시 H.C. Wainwright Buy
2019-11-19 개시 Cowen Outperform
2019-11-19 개시 Evercore ISI Outperform
2019-11-19 개시 Morgan Stanley Overweight
모두보기

Cabaletta Bio Inc 주식(CABA)의 최신 뉴스

pulisher
Nov 22, 2024

Cabaletta Bio, Inc. Set to Engage at Key Investor Conferences - MSN

Nov 22, 2024
pulisher
Nov 22, 2024

Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 - MSN

Nov 22, 2024
pulisher
Nov 21, 2024

Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com

Nov 21, 2024
pulisher
Nov 20, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim’s Healthcare Innovation Conference! - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

Cabaletta Bio Reports Q3 2024 Financial Results and Clinical Trial Advancements - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

Cabaletta Bio shares retain Buy rating as H.C. Wainwright sees robust treatment effect - Investing.com

Nov 19, 2024
pulisher
Nov 19, 2024

Cabaletta reports promising autoimmune therapy results By Investing.com - Investing.com Australia

Nov 19, 2024
pulisher
Nov 18, 2024

Cabaletta Bio Reports Q3 2024 Financial Results - TipRanks

Nov 18, 2024
pulisher
Nov 18, 2024

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Cabaletta reports promising autoimmune therapy results - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Cabaletta Bio’s (CABA) Buy Rating Reiterated at HC Wainwright - Defense World

Nov 18, 2024
pulisher
Nov 18, 2024

Inflammatory Myositis Treatment Market: Segmentation Trends, - openPR

Nov 18, 2024
pulisher
Nov 15, 2024

Cabaletta Bio (NASDAQ:CABA) Given New $12.00 Price Target at Wells Fargo & Company - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Cabaletta Bio stock hits 52-week low at $3.47 amid market challenges - Investing.com UK

Nov 15, 2024
pulisher
Nov 15, 2024

Cabaletta Bio's (CABA) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Cabaletta Bio Inc. (CABA) Quarterly 10-Q Report - Quartzy

Nov 15, 2024
pulisher
Nov 14, 2024

T. Rowe Price Investment Management, Inc. Reduces Stake in Cabal - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

Guggenheim maintains Buy on Cabaletta Bio with $23 target - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Guggenheim maintains Buy on Cabaletta Bio with $23 target By Investing.com - Investing.com UK

Nov 14, 2024
pulisher
Nov 14, 2024

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 14, 2024
pulisher
Nov 08, 2024

Cabaletta Bio to Spotlight Groundbreaking Cell Therapies at Guggenheim's Healthcare Innovation Conference! - MyChesCo

Nov 08, 2024
pulisher
Nov 06, 2024

Cabaletta Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference - The Manila Times

Nov 06, 2024
pulisher
Nov 06, 2024

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference - Yahoo Finance

Nov 06, 2024
pulisher
Nov 05, 2024

Vanguard Group Inc's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com

Nov 05, 2024
pulisher
Nov 04, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Nov 04, 2024
pulisher
Nov 03, 2024

UBS Initiates Coverage of Cabaletta Bio (CABA) with Buy Recommendation - MSN

Nov 03, 2024
pulisher
Oct 30, 2024

We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate - Yahoo Finance

Oct 30, 2024
pulisher
Oct 28, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Short Interest Down 28.9% in October - MarketBeat

Oct 28, 2024
pulisher
Oct 25, 2024

Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital + - Seeking Alpha

Oct 25, 2024
pulisher
Oct 22, 2024

Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of Cash - Seeking Alpha

Oct 22, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Holdings - Yahoo Finance

Oct 17, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Cabaletta Bio Inc Hol - GuruFocus.com

Oct 17, 2024
pulisher
Oct 14, 2024

Short Interest in Cabaletta Bio, Inc. (NASDAQ:CABA) Drops By 16.7% - MarketBeat

Oct 14, 2024
pulisher
Oct 14, 2024

Trading Day Review: Cabaletta Bio Inc (CABA) Gains Momentum, Closing at 4.21 - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Millennium Management LLC Grows Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Oct 12, 2024
pulisher
Oct 11, 2024

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential - MSN

Oct 11, 2024
pulisher
Oct 11, 2024

UBS sees significant upside for Cabaletta Bio despite recent share decline - Investing.com India

Oct 11, 2024
pulisher
Oct 10, 2024

Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential (NASDAQ:KYTX) - Seeking Alpha

Oct 10, 2024
pulisher
Oct 10, 2024

Healthy Upside Potential: Cabaletta Bio Inc (CABA) - SETE News

Oct 10, 2024
pulisher
Oct 10, 2024

UBS sees significant upside for Cabaletta Bio despite recent share decline By Investing.com - Investing.com South Africa

Oct 10, 2024
pulisher
Oct 10, 2024

Cabaletta Bio (NASDAQ:CABA) Now Covered by Analysts at UBS Group - MarketBeat

Oct 10, 2024
pulisher
Oct 10, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

A Guide To The Risks Of Investing In Cabaletta Bio Inc (CABA) - Knox Daily

Oct 09, 2024
pulisher
Oct 07, 2024

Cabaletta Bio Inc (CABA) stock analysis: A comprehensive overview - US Post News

Oct 07, 2024
pulisher
Oct 07, 2024

Cabaletta Bio Outlines Future Trials and Development Strategy - TipRanks

Oct 07, 2024
pulisher
Oct 04, 2024

Squarepoint Ops LLC Has $2.36 Million Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Oct 04, 2024
pulisher
Oct 04, 2024

Marshall Wace LLP Grows Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Oct 04, 2024
pulisher
Oct 02, 2024

Get in on Cabaletta Bio Inc’s (CABA) buy-in window today! - SETE News

Oct 02, 2024
pulisher
Oct 01, 2024

Should investors be concerned about Cabaletta Bio Inc (CABA)? - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

Cabaletta Bio Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle

Oct 01, 2024
pulisher
Oct 01, 2024

Cabaletta Bio secures lease terms through August 2026 - Investing.com India

Oct 01, 2024

Cabaletta Bio Inc (CABA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
자본화:     |  볼륨(24시간):